Rapid Therapeutic Announces Record Order for 100,000 Units of its Metered Dose Inhalers Addressing $9.3 Billion CBD Market

Rapid’s Rxoid branded inhalers deliver 98% bioavailable dose of CBD utilizing proprietary formulation blend

DALLAS, June 23, 2020 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), a fully-reporting, early stage, emerging biotech company focused on manufacturing and marketing aerosol delivery of cannabinoids, including CBD, in the legal hemp and cannabis space using Metered Dose Inhalers (MDIs), announced today that RTSL received an order for a 100,000 unit wholesale order of its Rxoid brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bioavailable dose of CBD directly to the systemic blood stream.

Donal R. Schmidt, Jr., Esq., Chairman and CEO stated, “Our Rxoid CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States and we are extremely pleased about our products’ acceptance throughout the medical community.”

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL has developed and perfected a new method of formulation and manufacturing to deliver pure CBD, CBG and/or THC and combinations thereof in legal jurisdictions to consumers through an FDA approved medical device known as a metered dose inhaler (MDI). The Rxoid MDI product line is manufactured in compliance with cGMP on FDA approved equipment. Non-THC Cannabinoids are not yet approved by the FDA but are legal to consume in TX and many other states and export to legal foreign jurisdictions.

Properly formulated MDIs deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is the most efficient method of delivery of an API other than an IV. RTSL’s MDIs are a safe replacement for vape pens and delivers a 98% bioavailable dose of CBD and/or THC directly to the systemic blood stream. The current vape market in the US is estimated to be $5 Billion.

An MDI is the replacement for vape pens as it uses no heat and needs no dangerous ingredients to work. In addition, MDIs are less expensive than any other route of delivery measured by blood serum levels. They are however expensive to formulate and manufacture so that they legally and properly work as an MDI under FTC rules on truth and labeling.

RTSL markets its Rxoid MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.

RTSL’s MDI products also can be purchased online at www.rxoid.com.